Tip:
Highlight text to annotate it
X
We're thrilled to launch this new Department of bioengineering and Therapeutic Sciences.
It brings together people in the School of Pharmacy, and the School of Medicine, interested
in developing novel, innovative therapies. The research collaborations are fantastic,
it couldn't have happened at any other place than UCSF because we're already a very collaborative
environment.
It's a department that focuses on the science of drug development, combining the engineering
aspects with the therapeutic science and the basic understanding of drug metabolism, pharmacokinetics/pharmacodynamics,
with the unique aspect in terms of what we bring to the drug development process. We
have strong interactions with industry because we do the types of work that, in fact, become
the rate-limiting step in drug development: moving from the animal to the human, understanding
toxicology, understanding how drugs break down.
The collection of technologies here, which is everything from a very early aspects of
drug discovery process through the translation in medicine, through novel approaches that
can help with clinical design make, I think, probably this the single most interesting
environment for collaboration of industries that exists. And potentially anywhere.
Absolutely delighted to have this inaugural symposium today. It's been a wonderful opportunity
to showcase the department that we have, and also to demonstrate to the outside world who
we are, where we are, and why we've been formed.
The Department of Bioengineering and Therapeutic Sciences is simply brilliant; it brings together
engineers and pharmaceutical scientists who can put together a new integrated discipline
that FDA will be very interested in.
The range of expertise that's coming into the department showcases the potential. I'm
excited of the colleagues that I have, because this colleagues can assist me moving my science
forward to clinical implementation.